Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2016
Price : $35 *
At a glance
- Drugs Pegargiminase (Primary) ; Doxorubicin
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Polaris Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 13 Apr 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 24 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016 as per ClinicalTrials.gov record.